- Home
- HRMY vs CRGY Comparison
HRMY vs CRGY Comparison
Compare HRMY & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- CRGY
- Stock Information
- Founded
- HRMY 2017
- CRGY 1986
- Country
- HRMY United States
- CRGY United States
- Employees
- HRMY N/A
- CRGY N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- CRGY Oil & Gas Production
- Sector
- HRMY Health Care
- CRGY Energy
- Exchange
- HRMY Nasdaq
- CRGY Nasdaq
- Market Cap
- HRMY 1.8B
- CRGY 2.5B
- IPO Year
- HRMY 2020
- CRGY N/A
- Fundamental
- Price
- HRMY $34.43
- CRGY $8.28
- Analyst Decision
- HRMY Strong Buy
- CRGY Buy
- Analyst Count
- HRMY 9
- CRGY 12
- Target Price
- HRMY $54.44
- CRGY $16.40
- AVG Volume (30 Days)
- HRMY 594.8K
- CRGY 3.1M
- Earning Date
- HRMY 08-05-2025
- CRGY 08-04-2025
- Dividend Yield
- HRMY N/A
- CRGY 5.48%
- EPS Growth
- HRMY 13.13
- CRGY N/A
- EPS
- HRMY 2.62
- CRGY N/A
- Revenue
- HRMY $744,852,000.00
- CRGY $3,223,618,000.00
- Revenue This Year
- HRMY $20.33
- CRGY $25.73
- Revenue Next Year
- HRMY $17.67
- CRGY N/A
- P/E Ratio
- HRMY $13.30
- CRGY N/A
- Revenue Growth
- HRMY 20.62
- CRGY 31.58
- 52 Week Low
- HRMY $26.47
- CRGY $6.83
- 52 Week High
- HRMY $41.61
- CRGY $16.94
- Technical
- Relative Strength Index (RSI)
- HRMY 64.26
- CRGY 38.83
- Support Level
- HRMY $33.76
- CRGY $8.96
- Resistance Level
- HRMY $35.08
- CRGY $9.56
- Average True Range (ATR)
- HRMY 0.87
- CRGY 0.39
- MACD
- HRMY 0.34
- CRGY -0.06
- Stochastic Oscillator
- HRMY 92.43
- CRGY 0.00
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.